Evidence map›Paper›PMID 42603795›Full record

ArticleCell death & disease2026

Loss of CD44 re-educates pancreatic cancer-associated fibroblasts modulating their fibrotic and immunosuppressive functions.

Sven Máté Treffert, Yvonne Madeleine Heneka, Julie Martin, Alessandra Gargano, Larissa Launhardt, Özlem Akilli, Eliana Stanganello, Geoffroy Andrieux, Dominique Hoch, Steffen Joachim Sonnentag and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sven Máté Treffert *Karlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany.
Yvonne Madeleine Heneka *Karlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany.ORCID http://orcid.org/0009-0006-9273-5427
Julie MartinKarlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany.
Alessandra GarganoTRON Translational Oncology at the University Medical Center, JGU-Mainz, Mainz, 55131, Germany.
Larissa LaunhardtTRON Translational Oncology at the University Medical Center, JGU-Mainz, Mainz, 55131, Germany.
Özlem AkilliTRON Translational Oncology at the University Medical Center, JGU-Mainz, Mainz, 55131, Germany.
Eliana StanganelloTRON Translational Oncology at the University Medical Center, JGU-Mainz, Mainz, 55131, Germany.
Geoffroy AndrieuxInstitute of Medical Bioinformatics and Systems Medicine, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, 79085, Germany.ORCID http://orcid.org/0000-0002-5389-9481
Dominique HochKarlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany.
Steffen Joachim SonnentagKarlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany.
Lisa-Marie MehnerKarlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany.
Leonel Munoz-SagredoKarlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany.
Michelle ChristKarlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany.
Véronique Orian-RousseauKarlsruhe Institute of Technology, Institute of Biological and Chemical Systems, Functional Molecular Systems (IBCS-FMS), Kaiserstraße 12, Karlsruhe, 76131, Germany. veronique.orian-rousseau@kit.edu.ORCID http://orcid.org/0000-0003-2939-9257

Funding

Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) EkoEstMed-FKZ 01ZZ2015Deutsche Forschungsgemeinschaft (German Research Foundation) OR124/24-1Helmholtz Association Materials Systems Engineering (MSE)
6 · The paper itself

Abstract

Pancreatic tumors are characterized by a prominent desmoplastic stroma that can account for up to 90% of the tumor. Given the marked upregulation of CD44, a family of transmembrane glycoproteins, in pancreatic cancer-associated fibroblasts (CAFs), we investigated its role in regulating myofibroblastic and inflammatory CAF phenotypes. Conditional deletion of Cd44 in fibroblastic cells in Cd44

Indexed as

Cancer-Associated FibroblastsHyaluronan ReceptorsPancreatic NeoplasmsAnimalsCell Line, TumorDendritic CellsFibrosisHumansMiceT-Lymphocytes, RegulatoryHyaluronan Receptors

Identifiers

PMID42603795
PMCPMC13477481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.